These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33093337)

  • 1. Innovations in targeted therapies for triple negative breast cancer.
    McCann KE; Hurvitz SA
    Curr Opin Obstet Gynecol; 2021 Feb; 33(1):34-47. PubMed ID: 33093337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in Targeted Therapies for Triple-Negative Breast Cancer.
    McCann KE; Hurvitz SA; McAndrew N
    Drugs; 2019 Jul; 79(11):1217-1230. PubMed ID: 31254268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolving management of metastatic triple negative breast cancer.
    Malhotra MK; Emens LA
    Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
    Weiss J; Glode A; Messersmith WA; Diamond J
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
    Moy B; Rumble RB; Come SE; Davidson NE; Di Leo A; Gralow JR; Hortobagyi GN; Yee D; Smith IE; Chavez-MacGregor M; Nanda R; McArthur HL; Spring L; Reeder-Hayes KE; Ruddy KJ; Unger PS; Vinayak S; Irvin WJ; Armaghani A; Danso MA; Dickson N; Turner SS; Perkins CL; Carey LA
    J Clin Oncol; 2021 Dec; 39(35):3938-3958. PubMed ID: 34324366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
    Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
    Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Therapies for Triple-Negative Breast Cancer.
    Lyons TG
    Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
    Tazzite A; Jouhadi H; Benider A; Nadifi S
    Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple-Negative Breast Cancer: Breast Tumors With an Identity Crisis.
    Nunnery SE; Mayer IA; Balko JM
    Cancer J; 2021 Jan-Feb 01; 27(1):2-7. PubMed ID: 33475287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
    Schreiber AR; Andress M; Diamond JR
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524
    [No Abstract]   [Full Text] [Related]  

  • 12. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
    Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M;
    Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Untangling Triple-Negative Breast Cancer Molecular Peculiarity and Chemo-Resistance: Trailing Towards Marker-Based Targeted Therapies.
    Kanwal B
    Cureus; 2021 Jul; 13(7):e16636. PubMed ID: 34458041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline
    Desai NV; Tan AR
    JCO Precis Oncol; 2023 May; 7():e2200446. PubMed ID: 37163718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
    Furlanetto J; Marmé F; Loibl S
    Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
    Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
    Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging biologic therapies for triple negative breast cancer.
    Shaikh SS; Emens LA
    Expert Opin Biol Ther; 2022 May; 22(5):591-602. PubMed ID: 32713217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
    Gupta T; Vinayak S; Telli M
    Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
    Nagayama A; Vidula N; Bardia A
    Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
    Sharma P
    Curr Treat Options Oncol; 2018 Apr; 19(5):22. PubMed ID: 29656345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.